- Home
- Solutions
- About Us
- Contact Us
- Careers
Poly (ADP-ribose) polymerase (PARP) inhibitors represent a groundbreaking class of targeted therapies for cancer treatment, significantly enhanced by patient-derived xenograft (PDX) models. These models effectively replicate tumor development and drug response, preserving the histopathological, genetic, and microenvironmental characteristics of the original tissues, making them among the most reliable preclinical models available. Alfa Cytology specializes in providing PDX models tailored for the development of PARP inhibitors.
High Fidelity to Patient Tumors
PDX models retain the histopathological and genetic characteristics of the original tumors, closely mimicking the complexity of human cancer.
Insights into Drug Resistance
Researchers can investigate mechanisms of resistance to PARP inhibitors within PDX models, facilitating the identification of potential combination therapies to overcome these challenges.
Longitudinal Studies
PDX models allow for the longitudinal study of tumor evolution and response to treatment over time, providing valuable insights into the dynamics of cancer progression.
Download our comprehensive guidelines to explore how PDX models can advance your PARP inhibitor development for cancer therapy. With our extensive expertise and integrated services, we are your trusted partner in accelerating cancer research and driving breakthroughs in diagnostics and therapeutics. For personalized services or further technical assistance, contact us to receive customized solutions tailored to your research needs.
